TriSalus Life Sciences (NASDAQ:TLSI) Upgraded by Northland Capmk to “Strong-Buy”

Northland Capmk upgraded shares of TriSalus Life Sciences (NASDAQ:TLSI) to a strong-buy rating in a research note published on Friday morning, Zacks.com reports.

Other equities research analysts have also recently issued reports about the company. Northland Securities assumed coverage on TriSalus Life Sciences in a research note on Friday. They set an “outperform” rating and a $12.50 target price on the stock. Oppenheimer started coverage on shares of TriSalus Life Sciences in a research report on Monday, September 16th. They issued an “outperform” rating and a $10.00 price objective on the stock. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $12.00 target price on shares of TriSalus Life Sciences in a research report on Thursday, June 27th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, TriSalus Life Sciences has a consensus rating of “Buy” and an average price target of $12.50.

TriSalus Life Sciences Price Performance

Shares of TLSI stock opened at $4.07 on Friday. The firm has a 50-day moving average of $4.74 and a 200-day moving average of $6.43. TriSalus Life Sciences has a one year low of $3.32 and a one year high of $10.42. The company has a market cap of $119.29 million, a P/E ratio of -1.63 and a beta of 0.47.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Wednesday, August 14th. The company reported ($0.21) EPS for the quarter. The business had revenue of $7.36 million for the quarter. As a group, research analysts expect that TriSalus Life Sciences will post -1.53 earnings per share for the current fiscal year.

Insider Buying and Selling at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela bought 7,520 shares of TriSalus Life Sciences stock in a transaction dated Thursday, September 12th. The stock was purchased at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the purchase, the chief executive officer now directly owns 377,382 shares of the company’s stock, valued at approximately $1,962,386.40. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 32.80% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

Several hedge funds have recently bought and sold shares of TLSI. Highbridge Capital Management LLC purchased a new position in shares of TriSalus Life Sciences during the 2nd quarter valued at $1,184,000. Wolverine Asset Management LLC bought a new stake in TriSalus Life Sciences during the second quarter valued at $240,000. Finally, Duquesne Family Office LLC boosted its stake in TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after buying an additional 110,966 shares during the period. Hedge funds and other institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.